Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KCL-440
CAS:<p>RS 57639 is a bioactive chemical.</p>Fórmula:C18H18N2O2Cor e Forma:SolidPeso molecular:294.35BPTF-IN-BZ1
<p>BPTF-IN-BZ1 is a BPTF inhibitor that possesses a high potency with a Kd of 6.3 nM.</p>Fórmula:C13H15ClN4OCor e Forma:SolidPeso molecular:278.74XY153
<p>XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.</p>Fórmula:C33H34FN3O4Cor e Forma:SolidPeso molecular:555.64JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SCor e Forma:SolidPeso molecular:599.62Azaphilone-9
CAS:<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Fórmula:C21H23BrO5Cor e Forma:SolidPeso molecular:435.3115:0 PG sodium
CAS:<p>15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.</p>Fórmula:C36H70NaO10PCor e Forma:SolidPeso molecular:716.90PRMT5-IN-3
CAS:<p>PRMT5-IN-3 is a PRMT5 inhibitor.PRMT5-IN-3 is a combined DNA damaging agent that is synthetically lethal to tumor cells.</p>Fórmula:C22H23F3N4O3Cor e Forma:SolidPeso molecular:448.44GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Fórmula:C20H18F2N6O5SCor e Forma:SolidPeso molecular:492.46P300-IN-4
<p>P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.</p>Fórmula:C29H28ClIN4O5Cor e Forma:SolidPeso molecular:674.91Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Fórmula:C24H25N7O2Cor e Forma:SolidPeso molecular:443.50ROPA
CAS:<p>ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.</p>Fórmula:C28H32O6Pureza:98%Cor e Forma:SolidPeso molecular:464.55CBP/p300-IN-18
<p>CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).</p>Fórmula:C25H27FN4O3Cor e Forma:SolidPeso molecular:450.51BET-IN-27
CAS:<p>BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.</p>Fórmula:C21H23N5O3SCor e Forma:SolidPeso molecular:425.5HDAC/Top-IN-1
CAS:<p>HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.</p>Fórmula:C29H25FN4O4Cor e Forma:SolidPeso molecular:512.53JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSCor e Forma:SolidPeso molecular:437.87BBC0403
CAS:<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Fórmula:C21H22N2O5Pureza:98.15%Cor e Forma:SolidPeso molecular:382.41JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Fórmula:C31H31F3N8O4Cor e Forma:SolidPeso molecular:639.64XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Fórmula:C19H25N3O5SCor e Forma:SolidPeso molecular:407.48(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OCor e Forma:SolidPeso molecular:402.92PARP1-IN-30
CAS:<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>Fórmula:C14H12ClNO4SCor e Forma:SolidPeso molecular:325.77KSQ-4279 (gentisate)
CAS:<p>KSQ-4279 (gentisate) (Compound Formula I) serves as an effective inhibitor of USP1 and a selective inhibitor of PARP1. This compound shows promise for use in cancer research.</p>Fórmula:C34H31F3N8O5Cor e Forma:SolidPeso molecular:688.66HIF-1/2α-IN-1
<p>HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.</p>Fórmula:C17H16N6O4Cor e Forma:SolidPeso molecular:368.35(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37W4275
CAS:<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Fórmula:C25H36N6O3Cor e Forma:SolidPeso molecular:468.59GSK789
CAS:<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Fórmula:C26H33N5O3Cor e Forma:SolidPeso molecular:463.57PARP10/15-IN-1
<p>PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].</p>Fórmula:C13H10N2O3SCor e Forma:SolidPeso molecular:274.3PAD-IN-2
CAS:<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Fórmula:C27H28ClN5O2Cor e Forma:SolidPeso molecular:490RK-582
CAS:<p>RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.</p>Fórmula:C27H35FN6O3Cor e Forma:SolidPeso molecular:510.6HDAC1-IN-8
CAS:<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Fórmula:C22H24N2O4Cor e Forma:SolidPeso molecular:380.437HDAC/HSP90-IN-4
<p>HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.</p>Fórmula:C20H23N3O6Cor e Forma:SolidPeso molecular:401.15869TDI-015051
CAS:<p>TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.</p>Fórmula:C22H22FN5O4SCor e Forma:SolidPeso molecular:471.505(Rac)-RG108
CAS:<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Fórmula:C19H14N2O4Cor e Forma:SolidPeso molecular:334.326JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Fórmula:C24H20F4N6O2Cor e Forma:SolidPeso molecular:500.45Dot1L-IN-1
CAS:<p>The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.</p>Fórmula:C32H36ClN9O2SPureza:98%Cor e Forma:SolidPeso molecular:646.21PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Fórmula:C23H27FN4O3Cor e Forma:SolidPeso molecular:426.484LSD1/2-IN-3
<p>LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07G-631
CAS:<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Fórmula:C19H22F2N6O3Cor e Forma:SolidPeso molecular:420.41AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H13ClFN5OCor e Forma:SolidPeso molecular:357.77AZ13824374
<p>AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.</p>Fórmula:C30H39FN8O2Cor e Forma:SolidPeso molecular:562.68LSD1-IN-13 hydrochloride
CAS:<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Fórmula:C23H30ClN3O2SCor e Forma:SolidPeso molecular:448.02LSD1-IN-35
CAS:<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Fórmula:C25H26N4O2SCor e Forma:SolidPeso molecular:446.57SMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Fórmula:C20H13ClN4O3Cor e Forma:SolidPeso molecular:392.795PARP1-IN-29
CAS:<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Fórmula:C18H16FN3O2Cor e Forma:SolidPeso molecular:325.34LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Cor e Forma:SolidPeso molecular:337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Fórmula:C18H18F2N6O3Cor e Forma:SolidPeso molecular:404.37Menin-MLL inhibitor 4
CAS:<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Fórmula:C32H38FN7O3Pureza:98%Cor e Forma:SolidPeso molecular:587.69KAT6A-IN-2
CAS:<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Fórmula:C23H29N5O5SCor e Forma:SolidPeso molecular:487.57AMI-408
CAS:<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Fórmula:C20H13Cl2N6NaO5SCor e Forma:SolidPeso molecular:543.32KAT6A-IN-1
CAS:<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Fórmula:C23H27N5O5SCor e Forma:SolidPeso molecular:485.56HLCL-61
CAS:<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Fórmula:C23H24N2OCor e Forma:SolidPeso molecular:344.45LSD1-IN-16
<p>LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43Bromodomain inhibitor-13
CAS:<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.43CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Fórmula:C18H18N4Cor e Forma:SolidPeso molecular:290.36SMARCA2-IN-2
CAS:<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Fórmula:C16H17N3Cor e Forma:SolidPeso molecular:251.33AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OCor e Forma:SolidPeso molecular:323.32PFI-6-COOH
CAS:<p>PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.</p>Fórmula:C23H21N3O6Cor e Forma:SolidPeso molecular:435.43NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Fórmula:C22H28N2O3Cor e Forma:SolidPeso molecular:368.47cis-4-Br-2,5-F2-PCPA
<p>cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Fórmula:C32H34F3N7O2Cor e Forma:SolidPeso molecular:605.65Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Fórmula:C19H19F2N7O3Cor e Forma:SolidPeso molecular:431.40CBP/p300-IN-2
CAS:<p>CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).</p>Fórmula:C27H29F2N7O2Pureza:98%Cor e Forma:SolidPeso molecular:521.56PRMT5-IN-1
CAS:<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Fórmula:C19H19ClN4O5Pureza:98%Cor e Forma:SolidPeso molecular:418.83PARP1/2-IN-4
CAS:<p>PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.</p>Fórmula:C23H30FN5O6Cor e Forma:SolidPeso molecular:491.51LSD1/HDAC-IN-1
CAS:<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C18H18N2O4SCor e Forma:SolidPeso molecular:358.41DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Fórmula:C15H8Cl2O3Cor e Forma:SolidPeso molecular:307.128SCR-7952
CAS:<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Fórmula:C19H15ClN4OCor e Forma:SolidPeso molecular:350.80XP-524
CAS:<p>XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.</p>Fórmula:C30H28N6O3SCor e Forma:SolidPeso molecular:552.65PARP14 inhibitor 2
CAS:<p>PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.</p>Fórmula:C25H32FN3O4SCor e Forma:SolidPeso molecular:489.60MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Fórmula:C65H87N9O8SCor e Forma:SolidPeso molecular:1154.51PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:566.63BET-IN-6
CAS:<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Fórmula:C22H20N2O6SPureza:98%Cor e Forma:SolidPeso molecular:440.47PRMT5-IN-19
<p>PRMT5-IN-19 is a potent, selective PRMT5 inhibitor with IC50 of 23.9 nM and 47 nM, showing anti-cancer activity by inducing apoptosis.</p>Fórmula:C25H24N4OCor e Forma:SolidPeso molecular:396.48Itareparib
CAS:<p>Itareparib is a PARP inhibitor with demonstrated antitumor activity.</p>Fórmula:C20H26FN3O2Cor e Forma:SolidPeso molecular:359.438HIF-1α-IN-4
<p>HIF-1α-IN-4 is an inhibitor of HIF-1α with IC50 of 24 nM in HEK293T cells which has potential antitumor effects.</p>Fórmula:C16H12N2O3Cor e Forma:SolidPeso molecular:280.28HIF-2α-IN-7
CAS:<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Fórmula:C18H9F6NO2Cor e Forma:SolidPeso molecular:385.26TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Cor e Forma:SolidPeso molecular:489.458(1-Nitroethene-1,2-diyl)dibenzene
CAS:<p>(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.</p>Fórmula:C14H11NO2Cor e Forma:SolidPeso molecular:225.24Trichostatin A S-isomer
CAS:<p>Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.</p>Fórmula:C17H22N2O3Pureza:98%Cor e Forma:SolidPeso molecular:302.37OM-153
CAS:<p>OM-153 blocks tankyrase 1 (IC50: 13 nM) and 2 (IC50: 2 nM), stifling WNT signaling and COLO 320DM cell growth.</p>Fórmula:C28H24FN7O2Cor e Forma:SolidPeso molecular:509.53CM-414
CAS:<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Fórmula:C23H29N5O4Pureza:98%Cor e Forma:SolidPeso molecular:439.51RL5a
CAS:<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Fórmula:C17H19N3OCor e Forma:SolidPeso molecular:281.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Fórmula:C18H20F6N4OCor e Forma:SolidPeso molecular:422.37HDAC-IN-47
<p>HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.</p>Fórmula:C17H20BrN3O4Cor e Forma:SolidPeso molecular:410.26JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Fórmula:C23H22Cl2N4OCor e Forma:SolidPeso molecular:441.35HDAC8-IN-2
<p>HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.</p>Fórmula:C21H16N2O5Cor e Forma:SolidPeso molecular:376.36Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Fórmula:C33H43FN6O3Cor e Forma:SolidPeso molecular:590.73MI-1481
CAS:<p>MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.</p>Fórmula:C29H30F3N7O2SPureza:98%Cor e Forma:SolidPeso molecular:597.65HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Fórmula:C26H22N4O2Cor e Forma:SolidPeso molecular:422.48WW437
<p>WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.</p>Fórmula:C23H27N5O4Cor e Forma:SolidPeso molecular:437.49MMSET-IN-1
CAS:<p>MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .</p>Fórmula:C18H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:423.47Equisetin
CAS:<p>Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.</p>Fórmula:C22H31NO4Pureza:98%Cor e Forma:SolidPeso molecular:373.49PAD4-IN-5
CAS:<p>PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).</p>Fórmula:C34H41N7O3Cor e Forma:SolidPeso molecular:595.734LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Fórmula:C31H40N6O2Cor e Forma:SolidPeso molecular:528.69(2S,3R)-LP99
CAS:<p>(2S,3R)-LP99 is a less active enantiomer of LP99.</p>Fórmula:C26H30ClN3O4SPureza:98%Cor e Forma:SolidPeso molecular:516.05HDAC-IN-32
<p>HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.</p>Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.41AFM-30a hydrochloride
<p>AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.</p>Fórmula:C24H28ClFN6O3Cor e Forma:SolidPeso molecular:502.97GSK3368715
CAS:<p>GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s</p>Fórmula:C20H38N4O2Pureza:98%Cor e Forma:SolidPeso molecular:366.54FT001
CAS:<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Fórmula:C25H29N3O4SPureza:99.9%Cor e Forma:SolidPeso molecular:467.58
